TNBC HDAC - Search

About 260,000 results

Any time

Open links in new tab

nih.gov
https://pmc.ncbi.nlm.nih.gov › articles
HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
The present review aims to discuss the recent developments in the research of new HDACIs directed against TNBC, with a particular focus on the discovery of chimeric compounds, which …
Other content from pmc.ncbi.nlm.nih.gov
See more
PubMed
https://pubmed.ncbi.nlm.nih.gov
HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
May 26, 2022 · Triple negative breast cancer (TNBC) is an urgent as well as huge medical challenge, which is associated with poor prognosis and responsiveness to chemotherapies. …
- PubMed
PubMed
https://pubmed.ncbi.nlm.nih.gov
Multiple screening approaches reveal HDAC6 as a novel ... - PubMed
Jan 15, 2021 · Triple-negative breast cancer (TNBC) is a subtype of breast cancer without a targeted form of therapy. Unfortunately, up to 70% of patients with TNBC develop resistance …
Studies of TNBC HDAC
PubMed
HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is an urgent as well as huge medical challenge, which is associated with poor prognosis and responsiveness to chemotherapies. Since epigenetic changes are highly implicated in TNBC tumorigenesis and development, inhibitors of histone deacetylases (HDACIs) could r...
Author: Cristina Macca…
Published: 2022/05/26
Keywords: anticancer; …
ScienceDirect
Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isoform!
Triple negative breast cancer (TNBC) is a highly aggressive breast cancer subtype characterized by the lack in the expression of estrogen and progesterone receptors, and human epidermal growth factor receptors 2. TNBC stands out among other breast cancers subtypes for its high aggressiveness and inv...
Published: 2024/12/05
Cited By: 0
Keywords: Triple nega…
PubMed
Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a subtype of breast cancer without a targeted form of therapy. Unfortunately, up to 70% of patients with TNBC develop resistance to treatment. A known contributor to chemoresistance is dysfunctional mitochondrial apoptosis signaling. We set up a phenotypic sma...
Author: Catríona M Do…
Published: 2021/01/15
Keywords: National In…
National Center for Biotechnology Information
Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises
Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 gene. It comprises approximately 15-20% of breast cancers (BCs). Unfortunately, TNBC’s treatment continues to be a clinical problem because of its relatively poor prognosis, its aggre...
Author: NIKOLAOS G…
Published: Sep-Oct 2017
Publication: Cancer G…
PubMed
HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows. Immunotherapy has shown promising results in various types of cancer, including breast cancer. Her...
Author: Manuela Terra…
Published: 2017/12/12
Keywords: HDAC inhi…
National Center for Biotechnology Information
Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide
Simple Summary The human body is composed of hundreds of different normal cell types. Some of the important and unique features of these normal cell types are inherited by the cancer cells that arise from them. Indeed, the activities of the tumor gene mutations are constrained by this normal cell i...
Author: Udayan Bhatta…
Published: 2023/01
Publication: Cancers (…
ScienceDirect
https://www.sciencedirect.com › science › article › pii
Tackling triple negative breast cancer with HDAC inhibitors: 6 is …
Dec 5, 2024 · In this review we showcase the latest evidence supporting the involvement of histone deacetylase 6 (HDAC6) in cancer pathways strictly related to TNBC subtype, also …
Springer
https://link.springer.com › article
Recent advancement of HDAC inhibitors against breast cancer
Jun 9, 2023 · Recent studies highlight the great potential impact of HDAC inhibitors (HDACis) in suppressing TNBC, even though clinical trials including a single HDACis demonstrated …
Nature
https://www.nature.com › articles
HDAC6 inhibitors sensitize non-mesenchymal triple-negative …
May 26, 2021 · Triple-negative breast cancer (TNBC) is a highly malignant type of breast cancer and lacks effective therapy. Targeting cysteine-dependence is an emerging strategy to treat …
- Author: Tahiyat Alothaim, Morgan Charbonneau, Xiaohu Tang
- Publish Year: 2021
People also ask
Does HDAC6 play a role in TNBC?
Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isoform! The evidence of the role of epigenetic players in TNBC is increasingly growing. We showcase the latest evidence supporting the involvement of HDAC6 in TNBC. We tracked the latest reports on novel HDAC6is with efficacy in TNBC models.
Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isof…
sciencedirect.com
Are HDAC inhibitors effective against TNBC?
Recent studies highlight the great potential impact of HDAC inhibitors (HDACis) in suppressing TNBC, even though clinical trials including a single HDACis demonstrated unsatisfactory outcomes against TNBC. New compounds created to achieve isoform selectivity and/or a polypharmacological HDAC strategy have also produced interesting results.
Recent advancement of HDAC inhibitors against breast cancer | Medica…
link.springer.com
Are HDACs involved in TNBC?
Since the involvement of HDACs in TNBC has been demonstrated, both unselective and selective HDACis have been investigated.
Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isof…
sciencedirect.com
Are novel hdac6is effective in TNBC models?
We tracked the latest reports on novel HDAC6is with efficacy in TNBC models. Triple negative breast cancer (TNBC) is a highly aggressive breast cancer subtype characterized by the lack in the expression of estrogen and progesterone receptors, and human epidermal growth factor receptors 2.
Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isof…
sciencedirect.com
Can HDACis be used to treat TNBC?
HDACis have been examined for the treatment of solid tumors, such as TNBC . Despite the dismal results of clinical trials that used single medications. Despite the fact that HDACis can inhibit tumor angiogenesis and metastasis, recent studies [7, 8] have demonstrated that they still have a major potential impact on the treatment of TNBC.
Recent advancement of HDAC inhibitors against breast cancer | Medica…
link.springer.com
Can HDAC inhibitor tucidinostat reduce TNBC cisplatin resistance?
The HDAC inhibitor Tucidinostat is proposed as a potential clinical approach for alleviating TNBC cisplatin resistance. A schematic diagram of the underlying mechanism indicates that HDAC2-mediated METTL3 delactylation promotes DNA damage repair and chemotherapy resistance in triple-negative breast cancer.
HDAC2‐Mediated METTL3 Delactylation Promotes DNA Damage Rep…
advanced.onlinelibrary.wiley.com
Feedback
nih.gov
https://pmc.ncbi.nlm.nih.gov › articles
Histone Deacetylases as New Therapeutic Targets in Triple …
HDAC inhibitors such as suberoylanilidehydroxamic acid (SAHA), sodium butyrate, mocetinostat, panobinostat, entinostat, YCW1 and N- (2-hydroxyphenyl)-2-propylpentanamide have shown …
ACS Publications
https://pubs.acs.org › doi
Discovery of a Novel G-Quadruplex and Histone …
Among the new compounds, a6 with the potent HDAC inhibitory and G4 stabilizing activity could induce more DNA G4 formation than SAHA and 1 in TNBC cells. Remarkably, a6 caused more G4-related DNA damage and G4 …
wiley.com
https://advanced.onlinelibrary.wiley.com › doi
HDAC2‐Mediated METTL3 Delactylation Promotes …
Feb 14, 2025 · Our study will elucidate the biological function of METTL3 lactylation modification in TNBC cells and highlight the nonclassical functional mechanism of Tucidinostat as a HDAC inhibitor for enhancing the efficacy of …
nature.com
https://www.nature.com › articles
LIFR inhibition enhances the therapeutic efficacy of HDAC
Oct 29, 2021 · We observed that both targeted knockdown of LIFR with CRISPR or treatment with EC359 enhanced the potency of four different HDACi in reducing cell viability, cell survival, …
People also search for
- hdac6 inhibitors tnbc
- histone deacetylases tnbc
Related searches for TNBC HDAC
- hdac6 inhibitors tnbc
- histone deacetylases tnbc
Pagination
- 1
- 2
- 3
- 4
- Next

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer

Multiple screening approaches reveal HDAC6 as a novel ... - PubMed

Tackling triple negative breast cancer with HDAC inhibitors: 6 is …

Recent advancement of HDAC inhibitors against breast cancer

HDAC6 inhibitors sensitize non-mesenchymal triple-negative …

Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isof…

Recent advancement of HDAC inhibitors against breast cancer | Medica…

Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isof…

Tackling triple negative breast cancer with HDAC inhibitors: 6 is the isof…

Recent advancement of HDAC inhibitors against breast cancer | Medica…

HDAC2‐Mediated METTL3 Delactylation Promotes DNA Damage Rep…

Histone Deacetylases as New Therapeutic Targets in Triple …

Discovery of a Novel G-Quadruplex and Histone …

HDAC2‐Mediated METTL3 Delactylation Promotes …

LIFR inhibition enhances the therapeutic efficacy of HDAC

Related searches for TNBC HDAC

Related searches for TNBC HDAC